Indogulf Cropsciences IPO Day 1 Live: Check GMP, subscription status, review, key dates. Apply or not?
Indogulf Cropsciences IPO price band has been fixed in the range of ₹ 105 to ₹ 111 per equity share of the face value of ₹ 10. The Indogulf Cropsciences IPO lot size is 135 equity shares and in multiples of 135 equity shares thereafter.
Indogulf Cropsciences IPO has reserved not more than 50% of the shares in the public issue for qualified institutional buyers (QIB), not less than 15% for non-institutional Institutional Investors (NII), and not less than 35% of the offer is reserved for retail investors.
The allocation of shares for the Indogulf Cropsciences IPO is expected to be determined on Tuesday, July 1, with refunds beginning on Wednesday, July 2. On the same day following the refunds, shares will be deposited into the demat accounts of the successful applicants. The listing price for Indogulf Cropsciences shares is anticipated to be announced on the BSE and NSE on Thursday, July 3.
Indogulf Cropsciences Limited focuses on the production of crop protection products, plant nutrients, and biological solutions within India. In 2019, the company achieved the successful production of Spiromesifen technical with a purity level of 96.5% and became one of the first domestic manufacturers of Pyrazosulfuron Ethyl technical with 97% purity in India.
The company operates four manufacturing facilities across Samba (Jammu & Kashmir) and Nathupur (Haryana), occupying approximately twenty acres, which includes two locations in Nathupur and one in Barwasni, Haryana.
Indogulf boasts a distribution network that spans 22 states and 3 Union Territories in India, backed by 169 business partners, 5,772 distributors, and 129 collaborators in 34 countries globally.
According to the red herring prospectus (RHP), the company's listed peers include Aries Agro Ltd (with a P/E ratio of 17.47), Basant Agro Tech India Ltd (with a P/E ratio of 44.58), Best Agrolife Ltd (with a P/E ratio of 12.23), Bhagiradha Chemicals & Industries Ltd (with a P/E ratio of 101.81), Heranba Industries Ltd (with a P/E ratio of 35.34), India Pesticides Ltd (with a P/E ratio of 41.62), and Dharmaj Crop Guard Ltd (with a P/E ratio of 18.02).
Subscription for the public issue will open at 10:00 IST during Thursday's deals.
According to Anand Rathi Research, in terms of valuation, the company is targeting a PE ratio of 24.6 times based on annualized FY25 figures, resulting in a post-issue market capitalisation of ₹ 7,015 million, making the offering reasonably priced.
Despite experiencing fluctuations in raw material prices over the past few years, the firm has demonstrated consistent growth in both its revenue and profits. The brokerage is confident that the company is positioned for long-term growth, supported by its backward-integrated manufacturing capabilities, dedicated research and development efforts, robust distribution and sales network, and a diverse range of products.
'Since the industry that company caters is cyclical, highly dependent on government's initiatives, shift in consumer preference for organic production and with its fully priced scenario we believe that, the company is long run growth story which requires timely mass initiatives for agricultural boost, increase awareness of sustainable farming. So we give 'SUBSCRIBE' rating for the issue,' said the brokerage.
The IPO consists of a new issuance of equity shares valued at ₹ 160 crore and a share sale of up to 36.03 lakh shares from promoters Om Prakash Aggarwal (HUF) and Sanjay Aggarwal (HUF).
The funds raised from the new issuance, amounting to ₹ 65 crore, will be allocated for meeting working capital needs, while ₹ 34.12 crore will go towards debt repayment, ₹ 14 crore for capital expenditures, and general corporate uses.
Systematix Corporate Services serves as the exclusive book-running lead manager, while Bigshare Services will act as the registrar for the issue.
Indogulf Cropsciences IPO GMP today or grey market premium is +11. This indicates Indogulf Cropsciences share price were trading at a premium of ₹ 11 in the grey market on Thursday, according to investorgain.com.
Considering the upper end of the IPO price band and the current premium in the grey market, the estimated listing price of Indogulf Cropsciences share price was indicated at ₹ 122 apiece, which is 9.91% higher than the IPO price of ₹ 111.
'Grey market premium' indicates investors' readiness to pay more than the issue price.
Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
4 minutes ago
- Business Standard
Smallcap stock soars 14% on heavy volumes, nears record high. Do you own?
Vimta Labs share price today: Shares of Vimta Labs have moved higher by 14 per cent to ₹578 on the BSE in Friday's intra-day trade amid heavy volumes in otherwise a weak market. The stock price of smallcap company is trading close to its record high level of ₹591.50 touched on February 12, 2025. In the past six trading days, the stock rallied 24 per cent. At 12:50 PM; Vimta Labs was quoting 13 per cent higher at ₹572, as compared to 0.7 per cent decline in the BSE Sensex. The average trading volumes on the counter jumped over five-fold. A combined 5.62 million equity shares representing 12.62 per cent of total equity of Vimta Labs have changed hands on the NSE (5.16 million shares) and BSE (0.46 million shares). Vimta Labs clarification on increase in volume of the shares Vimta Labs assumes that the movement in the share price of the company is purely due to market factors and not specifically related to the company. On July 21, the company has informed stock exchange that it has made all necessary prompt disclosures within the stipulated timelines and has not withheld any events/information/announcement (including impending announcement) including any price sensitive information that may have a bearing on the operation/performance of the company or on the price behaviour in the scrip. Vimta Labs Q1FY26 results In April to June 2025 quarter (Q1FY26), Vimta Labs reported revenue of ₹99.3 crore, up 31.4 per cent year-on-year (Y-o-Y), which was driven by pharmaceutical & food contract research and testing services. Profit after tax increased 35.9 per cent Y-o-Y to ₹18.9 crore from ₹13.9 crore in a year ago quarter. Earnings before interest, taxes, depreciation, and amortisation (Ebitda) margin improved to 35.7 per cent from 35.2 per cent. Vimta completed a successful United States Food and Drug Administration (USFDA) Good Clinical Practice (GCP) inspection with zero Form 483 observations and received a letter of cGMP compliance from ANSM (EMA) during the quarter. Vimta Labs company outlook Vimta Labs is positive about its growth prospects in clinical, pre-clinical, non-clinical, biopharmaceutical, pharma analytical, and electronics & electrical contract testing and research, all of which have a strong positive outlook despite the current global economic uncertainties, large competition, and stricter regulatory compliance requirements. The company has a strong customer base, and promising pipelines, which give it good visibility of growth over the medium term. Over the long term, the company expects it will strategically look at acquisition opportunities or alliances or partnerships to enhance its market reach, capabilities and service portfolio, to gain further market share. Vimta Labs, in its FY25 annual report, said that the trend in growth of the overseas market for the company is positive going forward. The domestic market continues to hold immense potential led by economic growth in the country. However, inflationary pressures in terms of cost of manpower, technology and material, and pricing pressures due to proliferation of laboratories in the country could be a risk to watch out for, the company said. About Vimta Labs Vimta Labs is a leading contract research and testing organisation, providing food, agri, bio/pharmaceutical, medical device, speciality chemical, and electronics companies an integrated scientific, technical, and regulatory expertise to support all stages of product development and manufacturing process. Vimta also provides environmental assessments and testing services.
&w=3840&q=100)
Business Standard
4 minutes ago
- Business Standard
Suryoday Small Finance Bank slips 7% on posting Q1 results; PAT 50% down
Suryoday Small Finance Bank shares slipped 6.7 per cent in trade on Friday, logging an intra-day low at ₹129.15 per share on BSE. The selling pressure on the counter came after the company posted Q1 results. At 12:38 PM, Suryoday Small Finance Bank share price was trading 4.08 per cent lower at ₹132.8 per share on BSE. In comparison, BSE Sensex was down 0.79 per cent at 81,536.82. The market capitalisation of the company stood at ₹1,411.46 crore. Suryoday Small Finance Bank Q1FY26 results Suryoday Small Finance Bank posted its first quarter ended June 30, 2025, results on Thursday, after market hours. In Q1, the company reported a 49.6 per cent decline in net profit to ₹35.3 crore, as compared to ₹70.1 crore a year ago. Its net interest income (NII) stood at ₹247.1 crore as compared to ₹293.2 crore a year ago, down 15.7 per cent. Gross advances grew 20 per cent year-on-year (Y-o-Y) to ₹10,846 crore as compared to ₹9,037 crore. Deposits grew 39 per cent to ₹11,312 crore as compared to ₹8,137 crore Y-o-Y. Current account savings account was flat Y-o-Y to 17.7 per cent. Gross non-performing asset (GNPA) increased 579 bps to 8.5 per cent and net non-performing asset (NNPA) was up 520 bps to 5.6 per cent. Disbursements stood at ₹2,261 crore in Q1 FY26 as compared to ₹1,740 crore in Q1FY25, an increase of 30 per cent Y-o-Y. The bank, in its statement, said that the microfinance sector's stress continued to weigh on the NII and credit costs, thereby impacting profitability for the quarter. However, with improved collection efficiency in Inclusive Finance and the underlying strength of the Bank's diversified portfolio-especially the secured retail and MSME segments-positions it well for improved performance going forward. It added: Looking ahead, the bank remains confident in its strategy of continuing focus on individual loans (Vikas Loan) in Inclusive Finance, diversifying the asset mix, strengthening the deposit franchise, and leveraging digital platforms. The investments made in credit protection mechanisms, customer acquisition through digital platforms, and focused execution in priority segments are expected to support consistent and profitable growth through FY26 and beyond. About Suryoday Small Finance Bank Limited Suryoday Small Finance Bank Limited is a scheduled commercial bank. Commencing its operations as an NBFC and for over a decade with a clear focus on serving customers in the unbanked and underbanked segments and promoting financial inclusion.
Mint
16 minutes ago
- Mint
M&B Engineering IPO: Price band set at ₹366-385 per share; check GMP, issue details, more
M&B Engineering IPO price band has been fixed in the range of ₹ 366 to ₹ 385 per equity share of the face value of ₹ 10. The M&B Engineering IPO date of subscription is scheduled for Wednesday, July 30 and will close on Friday, August 1. The allocation to anchor investors for the M&B Engineering IPO is scheduled to take place on Tuesday, July 29. The floor price is and the cap price are 36.60 times and 38.50 times the face value of the equity shares, respectively. The M&B Engineering IPO lot size is 38 equity shares and in multiples of 38 equity shares thereafter. M&B Engineering IPO has reserved not less than 75% of the shares in the public issue for qualified institutional buyers (QIB), not more than 15% for non-institutional Institutional Investors (NII), and not more than 10% of the offer is reserved for retail investors. The employee portion has been reserved equity shares aggregating up to ₹ 20 million. A discount of ₹ 36 per share is being offered to eligible employees bidding in the employee reservation portion. Tentatively, M&B Engineering IPO basis of allotment of shares will be finalised on Monday, August 4 and the company will initiate refunds on Tuesday, August 5 while the shares will be credited to the demat account of allottees on the same day following refund. M&B Engineering share price is likely to be listed on BSE and NSE on Wednesday, August 6. M&B Engineering IPO consists of a new issue of equity shares totaling ₹ 275 crore alongside an offer-for-sale (OFS) amounting to ₹ 375 crore from the promoters. Funds raised from the new issue are intended for acquiring equipment and machinery for the company's manufacturing plants, settling debts, covering working capital needs, and general corporate activities. Equirus Capital and DAM Capital Advisors serve as the book-running lead managers for the issuance. M&B Engineering ranks among the top providers in the nation for Pre-Engineered Buildings (PEB) and Self-Supported Roofing based on installed capacity, which stands at 103,800 MTPA for PEB and 1,800,000 square meters annually for Self-Supported Roofing. As per the red herring prospectus (RHP), the company's listed peers are Pennar Industries Ltd (with a P/E of 25.23), Bansal Roofing Products Ltd (with a P/E of 28.39 ), BirlaNU Ltd, Everest Industries Ltd, and Interarch Building Products Ltd (with a P/E of 33.69).
